Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Breast Cancer · HER2-positive Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Centre Eugène marquis, Rennes, France
Contact: Study coordinator (Thibault De la motte rouge, Md)

Study leads

Thibault De la Motte Rouge, MD
Principal Investigator
Centre Eugene Marquis

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Oligometastatic Breast Carcinoma · Breast Cancer · Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Berlin, Germany · Bremen, Germany

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Triple Negative Breast Cancer · Locally Advanced Breast Cancer · Recurrent Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Manchester, United Kingdom · Cambridge, United Kingdom